Noetik Partners With Memorial Sloan Kettering on Cancer AI

The collaboration gives Noetik access to Memorial Sloan Kettering's oncology dataset to advance cancer biology world models.

Updated on Nov. 19, 2026 in Cancer

Noetik Partners With Memorial Sloan Kettering on Cancer AI

AI company Noetik announced a collaboration with Memorial Sloan Kettering Cancer Center to advance cancer biology world models. The partnership grants Noetik access to proprietary data spanning a diversity of cancers taken during routine patient care.

Why it matters

The collaboration pairs Memorial Sloan Kettering's oncology expertise with Noetik's AI capabilities to build foundation models of human biology for oncology. Such models aim to improve prediction of how patients respond to therapy.

The dataset covers tens of thousands of patients and is anchored by MSK's Clinicogenomic Harmonized Oncologic Real-World Dataset (CHORD), curated by the Department of Pathology and Laboratory Medicine. No performance or outcome metrics for the resulting models were disclosed.

The players

Noetik

Noetik is an AI company building foundation models of human biology for oncology, working with pharmaceutical partner GSK.

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center is a leading New York-based cancer hospital and research institution that holds financial interests in Noetik.

The details

The data will enrich both model pre-training and post-training to improve therapeutic response prediction, combining MSK's research resources with Noetik's multimodal datasets derived from patient tumors. Noetik also works with the pharmaceutical company GSK, and MSK holds financial interests in Noetik.

Timeline

  1. November 19, 2026: Noetik announces the collaboration with Memorial Sloan Kettering Cancer Center.

Big Picture

The partnership extends the effort to train large AI foundation models on real-world clinical records, applying that approach to predicting how cancer patients respond to treatment.

Any resulting tools could eventually help oncologists anticipate how a patient will respond to a given therapy. The source reports no near-term changes to treatment options or insurance coverage.

The takeaway

Combining large clinical datasets with AI could sharpen how cancer treatments are matched to patients. Results from such efforts remain early, and readers should watch for published outcomes before expecting changes in care.

Further reading

Explore more on Cancer research and treatment developments.

More information

Learn more on the Noetik company website.

Source note: This article includes information reported by HPCwire.